Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BLU-222 + Fulvestrant + Ribociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BLU-222||BLU 222|BLU222||CDK2 Inhibitor 24||BLU-222 selectively inhibits CDK2, potentially leading to inhibition of cell growth and decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2306).|
|Fulvestrant||Faslodex||ICI 182,780||Hormone - Anti-estrogens 25||Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).|
|Ribociclib||Kisqali||LEE011||CDK4/6 Inhibitor 12||Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05252416||Phase Ib/II||BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant||(VELA) Study of BLU-222 in Advanced Solid Tumors||Recruiting||USA||0|